Protalix BioTherapeutics Inc. has provided an update on its clinical and commercial pipeline. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from selling goods during the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash, with no debt or outstanding warrants, and anticipates becoming cash flow positive in the first half of 2027. The company's commercial portfolio includes approved enzyme replacement therapies for Fabry disease and Gaucher disease, with market presence in the US, EU, and additional regions. In its development pipeline, Protalix highlights PRX-115, a recombinant PEGylated uricase candidate for uncontrolled gout, with Phase 2 studies expected to begin in the fourth quarter of 2025. The company also reports ongoing research in rare renal diseases and other NETs-related diseases. Key upcoming milestones include expanding market share for existing products, pursuing additional geographic approvals, and initiating a multinational Phase 2 trial for PRX-115. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.
